KR20180123214A - Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 - Google Patents

Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20180123214A
KR20180123214A KR1020187019391A KR20187019391A KR20180123214A KR 20180123214 A KR20180123214 A KR 20180123214A KR 1020187019391 A KR1020187019391 A KR 1020187019391A KR 20187019391 A KR20187019391 A KR 20187019391A KR 20180123214 A KR20180123214 A KR 20180123214A
Authority
KR
South Korea
Prior art keywords
cancer
activated
cells
receptor
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187019391A
Other languages
English (en)
Korean (ko)
Inventor
샤흐루즈 라비자데흐
패트릭 순-시옹
한스 클링에만
Original Assignee
난트 홀딩스 아이피, 엘엘씨
난트케이웨스트, 인크.
난트셀, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 난트 홀딩스 아이피, 엘엘씨, 난트케이웨스트, 인크., 난트셀, 인크. filed Critical 난트 홀딩스 아이피, 엘엘씨
Publication of KR20180123214A publication Critical patent/KR20180123214A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
KR1020187019391A 2015-12-09 2016-12-09 Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법 Ceased KR20180123214A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562265382P 2015-12-09 2015-12-09
US62/265,382 2015-12-09
PCT/US2016/066018 WO2017100709A1 (en) 2015-12-09 2016-12-09 Compositions and methods for treatment of her2 positive metastatic breast cancer

Publications (1)

Publication Number Publication Date
KR20180123214A true KR20180123214A (ko) 2018-11-15

Family

ID=59013368

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187019391A Ceased KR20180123214A (ko) 2015-12-09 2016-12-09 Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20180360881A1 (https=)
EP (1) EP3386522A4 (https=)
JP (1) JP2018537536A (https=)
KR (1) KR20180123214A (https=)
CN (1) CN109475576A (https=)
AU (1) AU2016366677A1 (https=)
CA (1) CA3007996A1 (https=)
WO (1) WO2017100709A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2567093A (en) 2016-07-15 2019-04-03 Viracta Therapeutics Inc Histone deacetylase inhibitors for use in immunotherapy
WO2018237325A1 (en) * 2017-06-22 2018-12-27 University Of Southern California Combination cancer therapy using chimeric antigen receptor engineered natural killer cells as chemotherapeutic drug carriers
EP3668538A4 (en) * 2017-08-15 2021-06-16 NantCell, Inc. HANK-CETUXIMAB COMBINATIONS AND PROCEDURES
CN110484507B (zh) * 2018-01-31 2023-10-13 温州医科大学 一种靶向肿瘤Her2的新型嵌合抗原受体T细胞的制备技术
IL321548A (en) * 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
TW202019487A (zh) * 2018-08-06 2020-06-01 日商第一三共股份有限公司 抗體-藥物結合物及微管蛋白抑制劑之組合
KR20240162586A (ko) 2018-10-31 2024-11-15 난트퀘스트, 인크. Pd-l1 키메라 항원 수용체-발현 nk 세포에 의한 pd-l1-양성 악성종양의 제거
EP4003376A4 (en) * 2019-07-26 2023-09-06 Nantkwest, Inc. CD16+NK-92 CELLS PRELOADED WITH ANTIBODIES AS AN EFFECTIVE THERAPEUTIC PRODUCT FOR TUMOR LYSIS
CA3184940A1 (en) 2020-07-07 2022-01-13 Jennifer Donglan WU Mic antibodies and binding agents and methods of using the same
CN112675313A (zh) * 2020-12-28 2021-04-20 烟台大学 连接曲妥珠单抗片段的美登素纳米粒组合物
CN114807237A (zh) * 2022-05-12 2022-07-29 广东普罗凯融生物医药科技有限公司 一种过表达CD16a的NK细胞的制备方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL215263B1 (pl) * 2002-02-25 2013-11-29 Elan Pharm Inc Kompozycja do przewleklego leczenia patologicznego zapalenia i zastosowanie natalizumabu lub jego immunologicznie aktywnego fragmentu do wytwarzania leku
CN101103043A (zh) * 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
EP3479844B1 (en) * 2005-04-15 2023-11-22 MacroGenics, Inc. Covalent diabodies and uses thereof
EP2161339A1 (en) * 2008-08-29 2010-03-10 F. Hoffmann-La Roche Ag ADCC with modified NK92 cells
EP4134085B1 (en) * 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
CN113699159A (zh) * 2014-03-28 2021-11-26 明尼苏达大学评议会 涉及经工程改造的cd16的多肽、细胞和方法
JP2018509459A (ja) * 2015-03-27 2018-04-05 ナントクエスト インコーポレイテッド がん治療薬との併用療法におけるｎｋ−９２細胞

Also Published As

Publication number Publication date
CN109475576A (zh) 2019-03-15
JP2018537536A (ja) 2018-12-20
US20180360881A1 (en) 2018-12-20
WO2017100709A1 (en) 2017-06-15
EP3386522A4 (en) 2019-06-19
AU2016366677A1 (en) 2018-07-26
CA3007996A1 (en) 2017-06-15
EP3386522A1 (en) 2018-10-17

Similar Documents

Publication Publication Date Title
KR20180123214A (ko) Her2 양성 전이성 유방암의 치료를 위한 조성물 및 방법
García-Foncillas et al. Distinguishing features of cetuximab and panitumumab in colorectal cancer and other solid tumors
Glassman et al. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
Lu et al. Folate receptor‐targeted immunotherapy: Induction of humoral and cellular immunity against hapten‐decorated cancer cells
KR100386492B1 (ko) 괴사유발물질과괴사에의해활성화되는물질을함유하는,종양및염증질환치료용배합제제로서의약제학적조성물
AU2014330895B2 (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
KR20140148412A (ko) 단일특이적 및 이중특이적인 항-igf-1r 및 항-erbb3 항체의 용량 및 투여
Kerbel Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs
Marti et al. The evolving landscape of HER2-directed breast cancer therapy
KR20190069493A (ko) 항-edb 항체 및 항체-약물 접합체
Yang et al. Immunotherapy for HER-2 positive breast cancer
EP3030268B1 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
US20250043023A1 (en) Targeting moiety-drug grafted immune cell compositions and methods of use
Noubissi Nzeteu et al. Nanoparticle-based immunotherapy of pancreatic cancer
JP2022017358A (ja) 癌の治療のための抗ｆｕｇｅｔａｃｔｉｃ剤の局所的送達
Nathoo et al. Epidermal growth factor receptor antagonists: novel therapy for the treatment of high-grade gliomas
Qin et al. CD19-targeted HSP90 inhibitor nanoparticle combined with TKIs reduces tumor burden and enhances T-cell immunity in murine B-cell malignancies
Mitsogianni et al. The changing treatment of metastatic her2-positive breast cancer
CN111225673A (zh) 亚德阿霉素组合治疗及方法
JP2018531229A6 (ja) 癌の治療のための抗ｆｕｇｅｔａｃｔｉｃ剤の局所的送達
JP2023549698A (ja) がんの治療のためのナノ粒子の組成物
Shen et al. Checkpoint inhibition and CAR T cells for the Treatment of Glioblastoma
Heimann et al. Monoclonal antibodies in therapy of solid tumors
JP7098518B2 (ja) 抗ｆｕｇｅｔａｃｔｉｃ特性を有する改変されたナチュラルキラー細胞およびその使用
Cooper et al. New Therapies on the Horizon

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20180706

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20190822

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201223

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230329

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230711

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230329

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I